Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck

Reto Abele; Michel Clavel; Silvio Monfardini; Utta Bruntsch; Josette Renard; Martine Van Glabbeke; Herbert M. Pinedo

doi:10.1016/0277-5379(87)90374-9

Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck

Reto Abele, Michel Clavel, Silvio Monfardini, Utta Bruntsch, Josette Renard, Martine Van Glabbeke, Herbert M. Pinedo

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

A phase II study of iproplatin was conducted in advanced squamous cell carcinoma of the head and neck both in patients previously treated with chemotherapy or not. Iproplatin was given intravenously every 4 weeks at the dose of 240-300 mg/m² without hydration. A total of 101 4-week courses was given to 50 eligible patients. No antitumor activity was detected. Drug-induced toxicity consisted in moderate myelosuppression, frequent but mild nausea and vomiting, and occasionally diarrhea and stomatitis. This study demonstrates that iproplatin given in this dose and schedule is devoid of activity in advanced squamous cell carcinoma of the head and neck.

Original language	English (US)
Pages (from-to)	387-389
Number of pages	3
Journal	European Journal of Cancer and Clinical Oncology
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/0277-5379(87)90374-9
State	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/0277-5379(87)90374-9

Cite this

@article{0f754a3bef1541f29c56bc1e5f258c11,

title = "Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck",

abstract = "A phase II study of iproplatin was conducted in advanced squamous cell carcinoma of the head and neck both in patients previously treated with chemotherapy or not. Iproplatin was given intravenously every 4 weeks at the dose of 240-300 mg/m2 without hydration. A total of 101 4-week courses was given to 50 eligible patients. No antitumor activity was detected. Drug-induced toxicity consisted in moderate myelosuppression, frequent but mild nausea and vomiting, and occasionally diarrhea and stomatitis. This study demonstrates that iproplatin given in this dose and schedule is devoid of activity in advanced squamous cell carcinoma of the head and neck.",

author = "Reto Abele and Michel Clavel and Silvio Monfardini and Utta Bruntsch and Josette Renard and {Van Glabbeke}, Martine and Pinedo, {Herbert M.}",

year = "1987",

doi = "10.1016/0277-5379(87)90374-9",

language = "English (US)",

volume = "23",

pages = "387--389",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "4",

}

TY - JOUR

T1 - Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck

AU - Abele, Reto

AU - Clavel, Michel

AU - Monfardini, Silvio

AU - Bruntsch, Utta

AU - Renard, Josette

AU - Van Glabbeke, Martine

AU - Pinedo, Herbert M.

PY - 1987

Y1 - 1987

N2 - A phase II study of iproplatin was conducted in advanced squamous cell carcinoma of the head and neck both in patients previously treated with chemotherapy or not. Iproplatin was given intravenously every 4 weeks at the dose of 240-300 mg/m2 without hydration. A total of 101 4-week courses was given to 50 eligible patients. No antitumor activity was detected. Drug-induced toxicity consisted in moderate myelosuppression, frequent but mild nausea and vomiting, and occasionally diarrhea and stomatitis. This study demonstrates that iproplatin given in this dose and schedule is devoid of activity in advanced squamous cell carcinoma of the head and neck.

AB - A phase II study of iproplatin was conducted in advanced squamous cell carcinoma of the head and neck both in patients previously treated with chemotherapy or not. Iproplatin was given intravenously every 4 weeks at the dose of 240-300 mg/m2 without hydration. A total of 101 4-week courses was given to 50 eligible patients. No antitumor activity was detected. Drug-induced toxicity consisted in moderate myelosuppression, frequent but mild nausea and vomiting, and occasionally diarrhea and stomatitis. This study demonstrates that iproplatin given in this dose and schedule is devoid of activity in advanced squamous cell carcinoma of the head and neck.

UR - http://www.scopus.com/inward/record.url?scp=0023110812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023110812&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90374-9

DO - 10.1016/0277-5379(87)90374-9

M3 - Article

C2 - 3609103

AN - SCOPUS:0023110812

SN - 0277-5379

VL - 23

SP - 387

EP - 389

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 4

ER -

Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this